{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:17:13Z","timestamp":1762633033879,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MYG 151211"],"award-info":[{"award-number":["MYG 151211"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cjco.2025.02.008","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:11:43Z","timestamp":1739880703000},"page":"1055-1061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART"],"prefix":"10.1016","volume":"7","author":[{"given":"Wade","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Sivaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ferreira-Legere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Abdel-Qadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-9584","authenticated-orcid":false,"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2025.02.008_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjco.2025.02.008_bib4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic burden of cardiovascular disease in type 2 diabetes: a systematic review","volume":"21","author":"Einarson","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.cjco.2025.02.008_bib5","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.02.008_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","article-title":"Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy","volume":"143","author":"Dave","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.02.008_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update","volume":"44","author":"Lipscombe","year":"2020","journal-title":"Can J Diabetes"},{"issue":"Suppl1","key":"10.1016\/j.cjco.2025.02.008_bib14","first-page":"S111","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjco.2025.02.008_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCOUTCOMES.114.001416","article-title":"The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services","volume":"8","author":"Tu","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2025.02.008_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","article-title":"Identifying diabetes cases from administrative data: a population-based validation study","volume":"18","author":"Lipscombe","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"177","key":"10.1016\/j.cjco.2025.02.008_bib17","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cjco.2025.02.008_bib18","doi-asserted-by":"crossref","first-page":"e016835","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2025.02.008_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.02.008_bib20","doi-asserted-by":"crossref","first-page":"e008381","DOI":"10.1161\/CIRCOUTCOMES.121.008381","article-title":"Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States","volume":"14","author":"Sangha","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjco.2025.02.008_bib21","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.9778\/cmajo.20220039","article-title":"Prescribing patterns and factors associated with sodium\u2013glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease","volume":"11","author":"Ozaki","year":"2023","journal-title":"CMAJ Open"},{"key":"10.1016\/j.cjco.2025.02.008_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"key":"10.1016\/j.cjco.2025.02.008_bib23","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.cjco.2025.02.008_bib24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0735-1097(21)02901-6","article-title":"Clinical practice patterns and attitudes about prescribing SGLT2 inhibitors at a single-center academic safety-net hospital","volume":"77","author":"Singhal","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.02.008_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12875-022-01928-z","article-title":"Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease\/ chronic kidney disease in Hong Kong: a qualitative study","volume":"23","author":"Ng","year":"2022","journal-title":"BMC Primary Care"},{"key":"10.1016\/j.cjco.2025.02.008_bib26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.cjco.2025.02.008_bib27","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s12325-024-02938-2","article-title":"Barriers and strategies to optimize the use of glucagon-like peptide 1 receptor agonists in people with type 2 diabetes and high cardiovascular risk or established cardiovascular disease: a Delphi consensus in Spain","volume":"41","author":"Botana L\u00f3pez","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.cjco.2025.02.008_bib28","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2025.02.008_bib29","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2025.02.008_bib30","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"145","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2025.02.008_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X25001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:14:26Z","timestamp":1762632866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X25001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589790X25001064"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2025.02.008","relation":{},"ISSN":["2589-790X"],"issn-type":[{"type":"print","value":"2589-790X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}